BioMed Research International, 2014 , 151479
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Disturbance of somatotopic spatial cognition and extra-territorial pain in carpal tunnel syndrome
Step 2: Clean Your Materials Wipe both vial tops with an alcohol swab
Hanssen, R
Perfil de seguridad El perfil de seguridad humano de Epitalon est esencialmente sin caracterizar en la literatura revisada por pares e indexada
